Oncternal Therapeutics IncNASDAQ:ONCT
- LAST PRICE1.2100
- TODAY'S CHANGE (%)-0.0800 (-6.2016%)
- Bid / Lots1.1500/ 2
- Ask / Lots1.3900/ 52
- Open / Previous Close1.2700 / 1.2900
- Day Range
- 52 Week Range
- Volume106,731
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ONCT |
|---|---|---|
| 09:32 ET | 651 | 1.27 |
| 09:35 ET | 100 | 1.27 |
| 09:57 ET | 335 | 1.26 |
| 10:00 ET | 100 | 1.25 |
| 10:09 ET | 3000 | 1.23 |
| 10:11 ET | 3850 | 1.23 |
| 10:13 ET | 2900 | 1.25 |
| 10:15 ET | 2421 | 1.23 |
| 10:18 ET | 307 | 1.235 |
| 10:20 ET | 5000 | 1.235 |
| 10:22 ET | 15231 | 1.23 |
| 10:33 ET | 400 | 1.25 |
| 10:36 ET | 600 | 1.25 |
| 11:32 ET | 748 | 1.25 |
| 12:03 ET | 100 | 1.24 |
| 12:53 ET | 310 | 1.25 |
| 12:57 ET | 7303 | 1.26 |
| 01:00 ET | 22423 | 1.19 |
| 01:02 ET | 394 | 1.18 |
| 01:18 ET | 142 | 1.195 |
| 01:20 ET | 5226 | 1.185 |
| 01:24 ET | 9276 | 1.2 |
| 01:27 ET | 1696 | 1.2086 |
| 01:29 ET | 1374 | 1.2384 |
| 01:33 ET | 14031 | 1.2 |
| 01:45 ET | 317 | 1.18 |
| 02:05 ET | 112 | 1.1884 |
| 02:07 ET | 225 | 1.187 |
| 02:18 ET | 100 | 1.195 |
| 03:17 ET | 1400 | 1.195 |
| 03:21 ET | 100 | 1.2 |
| 03:24 ET | 1350 | 1.1885 |
| 03:33 ET | 117 | 1.1801 |
| 03:35 ET | 264 | 1.19 |
| 03:57 ET | 200 | 1.18 |
| 04:00 ET | 421 | 1.21 |
Oct 22, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Oncternal Therapeutics Inc | 3.8M | -0.1x | --- |
Azitra Inc | 4.0M | 0.0x | --- |
Biodexa Pharmaceuticals PLC | 3.0M | 0.0x | --- |
Aditxt Inc | 3.2M | 0.0x | --- |
Lipella Pharmaceuticals Inc | 3.9M | -0.6x | --- |
Matinas BioPharma Holdings Inc | 4.5M | -0.1x | --- |
Company Information
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.
Contact Information
- Headquarters
- 12230 EL CAMINO REAL, SUITE 230SAN DIEGO, CA, United States 92130
- Phone
- 858-434-1113
- Fax
- 858-408-3010
Executives
- Independent Chairman of the Board
- David Hale
- President, Chief Executive Officer, Director
- James Breitmeyer
- Chief Financial Officer, Treasurer
- Richard Vincent
- Chief Technical Officer, Chief Scientific Officer
- Rajesh Krishnan
- General Counsel, Secretary
- Chase Leavitt
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.8M |
|---|---|
Revenue (TTM) | $1.8M |
Shares Outstanding | 3.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.29 |
EPS | $-12.19 |
Book Value | $10.19 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,040.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
